PriceTargets.com logo

Aspire Biopharma - ASBP Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.09 As of 12/4/2025 04:59 PM ET
▲ +0.0029 (3.25%)

This chart shows the closing price for ASBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aspire Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASBP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Aspire Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.09.

This chart shows the closing price for ASBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Aspire Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aspire Biopharma logo
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Read More

Today's Range

Now: $0.09
Low: $0.09
High: $0.10

50 Day Range

MA: $0.25
Low: $0.09
High: $0.44

52 Week Range

Now: $0.09
Low: $0.08
High: $15.80

Volume

13,070,735 shs

Average Volume

69,217,992 shs

Market Capitalization

$9.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Aspire Biopharma?

The following Wall Street sell-side analysts have issued reports on Aspire Biopharma in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ASBP.

What is the current price target for Aspire Biopharma?

0 Wall Street analysts have set twelve-month price targets for Aspire Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aspire Biopharma in the next year.
View the latest price targets for ASBP.

What is the current consensus analyst rating for Aspire Biopharma?

Aspire Biopharma currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe ASBP will underperform the market and that investors should sell shares of Aspire Biopharma.
View the latest ratings for ASBP.

What other companies compete with Aspire Biopharma?

Other companies that are similar to Aspire Biopharma include Kezar Life Sciences, ImmuCell, ZIVO Bioscience, Actinium Pharmaceuticals and Skye Bioscience. Learn More about companies similar to Aspire Biopharma.

How do I contact Aspire Biopharma's investor relations team?

Aspire Biopharma's physical mailing address is 1200 BROADWAY, FLOOR 3, NEW YORK, NY, 10038. The company's listed phone number is (561) 704-8527 and its investor relations email address is [email protected]. The official website for Aspire Biopharma is aspirebiolabs.com. Learn More about contacing Aspire Biopharma investor relations.